{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:13:18Z","timestamp":1767705198020,"version":"build-2065373602"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.3816\/clm.2009.s.021","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T06:04:58Z","timestamp":1254204298000},"page":"S261-S265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S3","title":["Nonmyeloablative Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era"],"prefix":"10.3816","volume":"9","author":[{"given":"Richard","family":"Champlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Rondon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobi","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Anderlini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin","family":"Alousi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chitra","family":"Hosing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uday","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzaffar","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borje","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.s.021_bib1","series-title":"Bone Marrow Transplantation","first-page":"595","article-title":"Allogeneic bone marrow transplantation for chronic myelogenous leukemia","author":"Champlin","year":"1994"},{"key":"10.3816\/CLM.2009.s.021_bib2","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V60.4.1038.1038","article-title":"Allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic or accelerated phase","volume":"60","author":"Champlin","year":"1982","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib3","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/blood.V98.7.2039","article-title":"Chronic myeloid leukemia: current treatment options","volume":"98","author":"Goldman","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib4","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1056\/NEJM199804023381405","article-title":"Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia","volume":"338","author":"Hansen","year":"1998","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.021_bib5","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/blood.V95.7.2219","article-title":"Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program","volume":"95","author":"McGlave","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood.V73.4.861.861","article-title":"Indications for marrow transplantation in chronic myelogenous leukemia","volume":"73","author":"Thomas","year":"1989","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib7","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJM198604243141701","article-title":"Hematologic remission cytogenic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia","volume":"314","author":"Talpaz","year":"1986","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.021_bib8","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V69.5.1280.1280","article-title":"Clinical investigation of human alpha interferon in chronic myelogenous leukemia","volume":"69","author":"Talpaz","year":"1987","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib9","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7326\/0003-4819-122-4-199502150-00003","article-title":"Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon therapy","volume":"122","author":"Kantarjian","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.3816\/CLM.2009.s.021_bib10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1200\/JCO.1999.17.1.284","article-title":"Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine","volume":"17","author":"Kantarjian","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.021_bib11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.021_bib12","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood-2004-06-2208","article-title":"Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia","volume":"105","author":"Quintas-Cardama","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib13","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferonalpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib14","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/cncr.23006","article-title":"Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.021_bib15","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/cncr.22569","article-title":"Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.021_bib16","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCRABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"1","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2006-07-035493","article-title":"Dasatinib (BMS-3 54825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure","volume":"109","author":"Quintas-Cardama","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib18","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","article-title":"Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia","volume":"109","author":"Hehlmann","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib19","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib20","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era","volume":"1","author":"Goldman","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib21","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood-2005-05-1816","article-title":"Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"107","author":"Jabbour","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0140-6736(84)92009-9","article-title":"How does bone marrow transplantation cure leukaemia?","volume":"2","author":"Gale","year":"1984","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.s.021_bib23","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1046\/j.1365-2141.1996.d01-1713.x","article-title":"Graft-versus-leukaemia: Understanding and using the alloimmune response to treat haematological malignancies","volume":"93","author":"Barrett","year":"1996","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.021_bib24","first-page":"18","article-title":"Harnessing graft-versus-malignancy: Nonmyeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy","volume":"111","author":"Champlin","year":"2000","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.021_bib25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1056\/NEJM198903303201303","article-title":"Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms","volume":"320","author":"Sullivan","year":"1989","journal-title":"New Eng J Med"},{"key":"10.3816\/CLM.2009.s.021_bib27","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-vs-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1702555","article-title":"Donor leukocyte infusions in acute lymphocytic leukemia","volume":"26","author":"Collins","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2009.s.021_bib29","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood.V97.3.631","article-title":"Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation","volume":"97","author":"Giralt","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib30","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib31","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib32","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","article-title":"Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy","volume":"89","author":"Giralt","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib33","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/sj.bmt.1700762","article-title":"Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation","volume":"19","author":"Bacigalupo","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2009.s.021_bib34","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0889-8588(05)70108-8","article-title":"Allogeneic hematopoietic transplantation as adoptive immunotherapy: induction of graft-vs-malignancy as primary therapy","volume":"13","author":"Champlin","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.3816\/CLM.2009.s.021_bib35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.021_bib36","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood.V96.8.2712","article-title":"Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"96","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib37","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V82.8.2310.2310","article-title":"Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose","volume":"82","author":"Drobyski","year":"1993","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib38","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood.V86.11.4337.bloodjournal86114337","article-title":"CD8+ depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: graft vs leukemia without graft vs. host disease","volume":"86","author":"Giralt","year":"1995","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib39","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-vs-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib40","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.bmt.1701224","article-title":"Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors","volume":"21","author":"Van Rhee","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2009.s.021_bib41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V95.1.67","article-title":"Comparison of single-dose and escalatingdose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia","volume":"95","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib42","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261","article-title":"Adoptive immunotherapy evaluating escalating doses of donor leukeocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separataiton of graft-versus-leukemia responses from graft-versus-host disease","volume":"86","author":"Mackinnon","year":"1995","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib43","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2002-02-0535","article-title":"Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase","volume":"101","author":"Or","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib44","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.hoc.2004.03.009","article-title":"Nonmyeloablative stem cell transplantation for chronic myeloid leukemia","volume":"18","author":"Qazilbash","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.3816\/CLM.2009.s.021_bib45","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","article-title":"Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia","volume":"111","author":"Sorror","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib46","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2007-04-085969","article-title":"Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia","volume":"110","author":"Kebriaei","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2002-08-2619","article-title":"HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen","volume":"102","author":"Radich","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib48","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","article-title":"Busulfan systemic exposure relative to regimen-related toxicity and acute graft-vs.-host diesase; defining a therapetuic window for IV BuCy2 in chronic myelogenous leukemia","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.3816\/CLM.2009.s.021_bib49","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/sj.bmt.1704461","volume":"33","author":"Thall","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2009.s.021_bib50","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.bbmt.2004.09.004","article-title":"Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation","volume":"10","author":"Anderlini","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.3816\/CLM.2009.s.021_bib51","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood.V100.5.1590.h81702001590_1590_1595","article-title":"Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia","volume":"100","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib52","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.22778","article-title":"Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.021_bib53","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood-2006-06-031682","article-title":"The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia","volume":"109","author":"Oehler","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib54","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","author":"Lee","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib55","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2006-02-001933","article-title":"Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure","volume":"108","author":"Jabbour","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.021_bib56","doi-asserted-by":"crossref","first-page":"1028a","DOI":"10.1182\/blood.V110.11.1028.1028","article-title":"Nonmyeloablative allogeneic transplantation in the imatinib era: three chances to achieve molecular remission in CML","volume":"110","author":"Champlin","year":"2007","journal-title":"Blood"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:19:29Z","timestamp":1761563969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":56,"alternative-id":["S1557919011703493"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.s.021","relation":{},"ISSN":["1557-9190"],"issn-type":[{"type":"print","value":"1557-9190"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonmyeloablative Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma and Myeloma","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLM.2009.s.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}